Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Semaglutide around knee replacement surgery
A pilot RCT sets out a 48-week semaglutide protocol around total knee replacement in obese patients. Here is what the paper covers and what remains unanswered.
NITs in MASH: disease-activity vs response
A 2026 letter argues non-invasive liver tests after semaglutide reflect disease activity, not validated response. Here is what that means for MASH trial design.
Semax and WADA: Is It Prohibited in Sport?
Semax is not explicitly named on the WADA Prohibited List, but S2 catch-all language creates genuine ambiguity. Here is what athletes need to know.
What is Semax? A plain-English explainer
Semax is a synthetic neuropeptide licensed in Russia for stroke recovery and unapproved in the EU, UK, and US. Here is what the research actually shows.
TB-500 dosing: what the trials used
The 2 mg weekly range circulating online has no human trial behind it. Here is what published thymosin beta-4 studies actually administered, trial by trial.
A short history of TB-500
TB-500 (thymosin beta-4) was first sequenced in 1981. Four decades on, it has no approved human use and only one controlled trial, in eye disease.
GH-IGF1 peptides: the clinical evidence gap
A 2026 Frontiers review maps the gap between trial data and self-administration practice for CJC-1295, ipamorelin, and related GH-axis peptides.
GLP-1 agonists in adolescent obesity: NMA
A July 2026 network meta-analysis found semaglutide 2.4 mg led on weight reduction in adolescents with obesity. Most comparisons were indirect.
GLP-1 drugs in pediatric obesity
Liraglutide and semaglutide carry regulatory approval for adolescents with obesity. A 2026 review maps what the trials found and what gaps remain.
Semaglutide lowers blood eosinophil counts
A real-world study of 371 adults found semaglutide cut blood eosinophil counts, with a larger effect in non-obese participants.
How long before incretins help in HFpEF?
A 2026 meta-analysis finds semaglutide and tirzepatide cut worsening HF events in HFmrEF/HFpEF, with sustained benefit from roughly five months onward.
Incretin drugs for T2D: 2026 NMA results
A 2026 network meta-analysis of 102 trials and 98,693 T2D patients ranked tirzepatide first for glycaemic control and retatrutide first for weight loss.